Review on the comparison of effectiveness between denosumab and bisphosphonates in post-menopausal osteoporosis.
10.1016/j.afos.2016.03.003
- Author:
Biju BENJAMIN
1
;
Mridula Ambwani BENJAMIN
;
Myint SWE
;
Sandheep SUGATHAN
Author Information
1. Department of Orthopaedics, Royal College of Medicine Perak, University Kuala Lumpur, Malaysia. bijuben@yahoo.com
- Publication Type:Randomized Controlled Trial ; Review
- Keywords:
Denosumab;
Bisphosphonates;
Post-menopausal osteoporosis;
Bone mineral density;
C-telopeptide
- MeSH:
Aged;
Bone Density;
Bone Remodeling;
Denosumab*;
Diphosphonates*;
Female;
Follow-Up Studies;
Hip;
Humans;
Osteoporosis;
Osteoporosis, Postmenopausal*;
Prospective Studies;
RANK Ligand;
Spine;
Wrist
- From:Osteoporosis and Sarcopenia
2016;2(2):77-81
- CountryRepublic of Korea
- Language:English
-
Abstract:
OBJECTIVE: Osteoporosis is a rapidly rising cause of concern for elderly patients. Various classes of drugs are available in the market. Bisphosphonates are considered as a first-line therapy for the prevention and treatment. Denosumab is an antiresorptive agent which is a RANK ligand inhibitor. There is a scarcity of comparison between these two classes of drugs. The aim of this study is to compare efficacy of Bisphosphonates and Denosumab in various parameters. MATERIALS AND METHODS: Literature search was done for randomized controlled trials (RCTs) comparing bisphosphonates with denosumab. RCTs with a treatment period of at least one year with a baseline bone mineral density (BMD) and bone turnover markers (BTM) and follow up values at one year were included in the study. All included studies were also analysed for complications. The study has also been registered in PROSPERO International prospective register of systematic reviews. RESULTS: A total of five RCTs were identified providing data on 3751 participants. In all five studies, the BMD changes at both hip and spine were statistically significant in favour of denosumab. Result was similar in three studies that studied BMD changes at the wrist. Denosumab also produced significant reduction in BTM as early as one month, but at one year there was no difference compared to the bisphosphonates. There was no statistically significant differences in the complication rates. CONCLUSION: Though both bisphosphonates and denosumab were effective with similar side effects, the latter was statistically superior in increasing the BMD and reducing the BTM.
